Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chularat Hospital Public Company Limited (CHG.BK)
THB1.61
+0.00 (+0.00%)
TH SET Healthcare Medical - Care Facilities
Address
88/8-9, Teparak Km. 15 Road 10540
Samut Prakan, TH
Samut Prakan, TH
CEO
Jedsada Chokdamrongsuk
Website
chularat.com
IPO
2013-05-16
ISIN TH4539010Z03
Also trades on
Stock Exchange of Thailand · CHG-R.BK (THB)
Stock Exchange of Thailand · CHG.BK (THB)
Description
Chularat Hospital Public Company Limited is a healthcare provider primarily operating clinics and hospitals across Thailand. The company's activities are structured into two main divisions: Hospital Operations and Other Businesses. In addition to its medical facilities, it also engages in the distribution of medical instruments and dietary supplement products. As of December 31, 2021, its network encompassed 14 branches of clinics and hospitals. The company was founded in 1986 and is headquartered in Samut Prakan, Thailand.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
THB1.61
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
30M
Beta
0.12
Float Shares
4.86B
Free Float %
44.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.14% | -1.44% | -3.52% | -18.45% | -6.16% | -8.67% | -25.14% | -55.23% | -57.45% | -50.00% | +57.47% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.61
DCF (Unlevered)
5.68
+252.7%
DCF (Levered)
4.29
+166.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
78% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | -1 |
| Sell | 1 | 0 |
| Strong Sell | 1 | 0 |
Quality scores
Altman Z-Score
6.55
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
4 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Care Facilities: +10.2%+1.3% Q1'26: +4.5% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%-3.7% Q1'26: +9.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+12.7% Q1'26: +4.1% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+14.2% ★ Q1'26: +14.2% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+13.4% ★ Q1'26: +13.1% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+0.0% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×0.36× ★ Q1'26: 0.34× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 8 EPS Ana. |
Dec 2027 9 Rev. Ana. 9 EPS Ana. |
Dec 2028 7 Rev. Ana. 7 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.15B
est: 3.16B (-0.1%)
|
3.64B
est: 3.64B (-0.1%)
|
3.88B
est: 3.91B (-0.9%)
|
4.41B
est: 4.38B (+0.6%)
|
5.17B
est: 5.11B (+1.1%)
|
5.43B
est: 5.40B (+0.6%)
|
11.74B
est: 11.08B (+5.9%)
|
10.10B
est: 10.27B (-1.6%)
|
7.73B
est: 8.52B (-9.3%)
|
8.24B
est: 8.28B (-0.6%)
|
8.35B
est: 8.29B (+0.7%)
|
8.70B
8.65B – 8.75B
+4.9% YoY
|
9.20B
8.98B – 9.44B
+5.8% YoY
|
9.97B
9.88B – 10.05B
+8.4% YoY
|
| EBITDA |
835.19M
est: 1.00B (-16.9%)
|
907.74M
est: 1.16B (-21.6%)
|
966.82M
est: 1.24B (-22.3%)
|
1.06B
est: 1.39B (-23.7%)
|
1.22B
est: 1.63B (-25.1%)
|
1.46B
est: 1.72B (-15.0%)
|
5.65B
est: 3.53B (+60.1%)
|
3.95B
est: 3.27B (+20.9%)
|
1.81B
est: 2.60B (-30.3%)
|
1.78B
est: 2.53B (-29.6%)
|
1.69B
est: 2.53B (-33.2%)
|
2.65B
2.64B – 2.67B
+4.9% YoY
|
2.80B
2.74B – 2.88B
+5.8% YoY
|
3.04B
3.01B – 3.06B
+8.4% YoY
|
| EBIT |
663.32M
est: 846.56M (-21.6%)
|
692.55M
est: 975.97M (-29.0%)
|
710.01M
est: 1.05B (-32.3%)
|
785.25M
est: 1.18B (-33.2%)
|
885.95M
est: 1.37B (-35.3%)
|
1.10B
est: 1.45B (-23.8%)
|
5.30B
est: 2.97B (+78.1%)
|
3.56B
est: 2.75B (+29.4%)
|
1.37B
est: 2.18B (-37.1%)
|
1.28B
est: 2.12B (-39.6%)
|
1.18B
est: 2.12B (-44.3%)
|
2.22B
2.21B – 2.24B
+4.9% YoY
|
2.35B
2.30B – 2.42B
+5.8% YoY
|
2.55B
2.53B – 2.57B
+8.4% YoY
|
| Net Income |
538.38M
est: 408.13M (+31.9%)
|
564.29M
est: 600.48M (-6.0%)
|
565.44M
est: 571.25M (-1.0%)
|
633.88M
est: 704.75M (-10.1%)
|
705.24M
est: 753.73M (-6.4%)
|
876.62M
est: 872.40M (+0.5%)
|
4.20B
est: 3.21B (+30.8%)
|
2.78B
est: 3.04B (-8.6%)
|
1.05B
est: 1.06B (-0.9%)
|
965.22M
est: 1.08B (-11.0%)
|
929.37M
est: 1.02B (-8.5%)
|
1.01B
1.00B – 1.01B
-0.4% YoY
|
1.08B
1.01B – 1.12B
+6.7% YoY
|
1.18B
950.44M – 1.48B
+9.3% YoY
|
| SGA |
425.89M
est: 341.56M (+24.7%)
|
493.82M
est: 393.77M (+25.4%)
|
550.85M
est: 423.03M (+30.2%)
|
570.07M
est: 474.12M (+20.2%)
|
672.38M
est: 552.78M (+21.6%)
|
673.20M
est: 584.23M (+15.2%)
|
821.27M
est: 1.20B (-31.5%)
|
934.88M
est: 1.11B (-15.9%)
|
910.77M
est: 952.05M (-4.3%)
|
1.13B
est: 925.63M (+21.8%)
|
1.18B
est: 926.41M (+27.6%)
|
971.94M
966.09M – 978.23M
+4.9% YoY
|
1.03B
1.00B – 1.06B
+5.8% YoY
|
1.11B
1.10B – 1.12B
+8.4% YoY
|
| EPS |
0.05
est: 0.04 (+32.1%)
|
0.05
est: 0.05 (-6.6%)
|
0.05
est: 0.05 (-1.8%)
|
0.06
est: 0.06 (-10.1%)
|
0.06
est: 0.07 (-6.5%)
|
0.08
est: 0.08 (+0.5%)
|
0.38
est: 0.29 (+30.1%)
|
0.25
est: 0.27 (-6.4%)
|
0.10
est: 0.10 (-0.9%)
|
0.09
est: 0.10 (-10.9%)
|
0.08
est: 0.09 (-6.8%)
|
0.09
0.09 – 0.09
+0.5% YoY
|
0.10
0.09 – 0.10
+5.9% YoY
|
0.10
0.09 – 0.13
+5.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.04B
OE per share TTM
0.09
Owner's Yield
6.87%
Maintenance CapEx ratio
19.78%
Maint CapEx / Avg PPE
63.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 17 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Emerging Markets Equity Income UCITS ETF DEMD.L | 0.09% | 238.4K | 0.46% |
| 2 | WisdomTree Emerging Markets Equity Income UCITS ETF - Acc DEMR.L | 0.09% | 238.4K | 0.46% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 21.6K | 0.56% |
| 4 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 21.0K | 0.44% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 52.4K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 23.2K | 0.48% |
| 7 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 114.7K | 0.39% |
| 8 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 4.2K | 0.22% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 12.5K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 6.7K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
236.3K
Shares Outstanding
11.00B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Suchai Laoveerawat | Deputy Medical Director & Executive Director | 440.0K | — |
| Jedsada Chokdamrongsuk | Chief Executive Officer & Director | 425.0K | — |
| Wandee Pitsanuvanavech | Head of Compliance, Deputy CEO & Administrative Director | 75.0K | female |
| Chutima Pincharean | Deputy Chief Executive Officer | 15.0K | — |
| Yudthana Sanguansakdikosol | Deputy Chief Executive Officer | 15.0K | — |
| Rasika Bangpong | Chief Accounting Manager | — | female |
| Suppachoke Rojcheewin | Chief Financial Officer | — | male |
| Khemkulkorn Toomthong | Head of Internal Audit & Internal Audit Manager | — | female |
| Sirinapha Lakhonchai | Company Secretary | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CHG.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
